The use of biologics (peptide and protein based drugs) has increased significantly over the
past few decades. However, their development has been limited by their short half-life …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
treatments for type 2 diabetes, lowering glycated haemoglobin (HbA 1c) and weight, but are …

Importance Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1
receptor agonist, with other classes of glucose-lowering therapy. Objective To compare …

Background Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor
agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly …

Background Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-
1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the …

Glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) are proglucagon
derived peptides that are released from gut endocrine cells in response to nutrient intake …

ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are highly
potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body …

Drugs based on peptides and proteins (PPs) have been widely used in medicine, beginning
with insulin therapy in patients with diabetes mellitus over a century ago. Although the oral …

was superior on change in HbA1c, but only slightly better on change in bodyweight. 11
When discussing the choice between a GLP-1 receptor agonist and an SGLT2 inhibitor, the …

T2DM (type 2 diabetes mellitus) is a chronic and progressive illness with high morbidity and
death rates. Oral semaglutide (Rybelsus®) is a combination of semaglutide, a glucagon-like …